Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
This guide reviews which stablecoins are compliant and the standards they must meet. It helps you spot red flags and choose compliant options with confidence.
19,334 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
A leading analyst has reiterated a $250 SpaceX target, arguing that SpaceX's physical AI capabilities could reshape r...
Real estate lenders and agents are adopting an education-first approach that centers on trust and client empowerment....
Retail traders on Robinhood are flocking to a high-yield FANG income ETF, chasing monthly payouts even as upside is c...
A disappointing sale of 7-year notes underscores investor caution as Iran war fears rise. Traders point to a shifting...
Two seniors were manipulated into mailing cash after alarming scam calls, triggering a statewide investigation and a ...
Alibaba's profits falling here's headlines grab attention, but the real story is a company in transition. This guide ...
OpenAI teams with Broadcom to introduce its first custom AI accelerator, Jalapeño. The move signals a broader strateg...
Women are breaking into top-paying, traditionally male-dominated fields. In 2026, surgeons, airline pilots, and softw...
A Knicks star’s Broadway moment becomes a teachable moment for personal finance. Learn practical tips to fund experie...
FuboTV’s reverse split failed to spark a lasting rally, with shares sliding as the company reports rising revenue but...
Retirees face a stubborn reality: utility bills keep arriving. A disciplined mix of dividend growth stocks, inflation...